Comparison of Acorda Therapeutics Inc. (ACOR) and Trillium Therapeutics Inc. (NASDAQ:TRIL) – MS Wkly

This is therefore a contrasting of the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation in Acorda Therapeutics Inc. (NASDAQ:ACOR) and Trillium Therapeutics Inc. (NASDAQ:TRIL). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

In table 1 we can see Acorda Therapeutics Inc. and Trillium Therapeutics Inc.s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has Acorda Therapeutics Inc. and Trillium Therapeutics Inc.s return on equity, net margins and return on assets.

Analyst Recommendations

Acorda Therapeutics Inc. and Trillium Therapeutics Inc. Ratings and Recommendations are available in the next table.

Acorda Therapeutics Inc.s upside potential currently stands at 261.71% and an $8.88 average target price.

Insider and Institutional Ownership

Institutional investors owned 0% of Acorda Therapeutics Inc. shares and 40.67% of Trillium Therapeutics Inc. shares. About 1.5% of Acorda Therapeutics Inc.s share are owned by insiders. Insiders Comparatively, owned 0.26% of Trillium Therapeutics Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Acorda Therapeutics Inc. has stronger performance than Trillium Therapeutics Inc.

Summary

Acorda Therapeutics Inc. beats on 6 of the 11 factors Trillium Therapeutics Inc.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinsons disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinsons disease; SYN120, which is in Phase II clinical trial to treat Parkinsons disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Womens Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Continued here:
Comparison of Acorda Therapeutics Inc. (ACOR) and Trillium Therapeutics Inc. (NASDAQ:TRIL) - MS Wkly